FDA Approval Summary: Belzutifan for VHL Disease Tumors—Letter

Jonathan Q. Trinh; Moataz Ellithi; Nicole Shonka; Raymond C. Bergan

doi:10.1158/1078-0432.CCR-22-2968

FDA Approval Summary: Belzutifan for VHL Disease Tumors—Letter

Jonathan Q. Trinh
, Moataz Ellithi
, Nicole Shonka
, Raymond C. Bergan

Cancer Center

University of Nebraska Medical Center

Research output: Contribution to journal › Letter › peer-review

6 Scopus citations

Original language	English
Pages (from-to)	684
Number of pages	1
Journal	Clinical Cancer Research
Volume	29
Issue number	3
DOIs	https://doi.org/10.1158/1078-0432.CCR-22-2968
State	Published - Feb 1 2023

Access to Document

10.1158/1078-0432.CCR-22-2968

Cite this

@article{015ab1663ce54cecb8658f2b7dfa9b9e,

title = "FDA Approval Summary: Belzutifan for VHL Disease Tumors—Letter",

author = "Trinh, \{Jonathan Q.\} and Moataz Ellithi and Nicole Shonka and Bergan, \{Raymond C.\}",

year = "2023",

month = feb,

day = "1",

doi = "10.1158/1078-0432.CCR-22-2968",

language = "English",

volume = "29",

pages = "684",

journal = "Clinical Cancer Research",

issn = "1078-0432",

number = "3",

}

TY - JOUR

T1 - FDA Approval Summary

T2 - Belzutifan for VHL Disease Tumors—Letter

AU - Trinh, Jonathan Q.

AU - Ellithi, Moataz

AU - Shonka, Nicole

AU - Bergan, Raymond C.

PY - 2023/2/1

Y1 - 2023/2/1

UR - https://www.scopus.com/pages/publications/85147187126

U2 - 10.1158/1078-0432.CCR-22-2968

DO - 10.1158/1078-0432.CCR-22-2968

M3 - Letter

C2 - 36722140

AN - SCOPUS:85147187126

SN - 1078-0432

VL - 29

SP - 684

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 3

ER -

FDA Approval Summary: Belzutifan for VHL Disease Tumors—Letter

Access to Document

Other files and links

Fingerprint

Cite this